Baird raised the firm’s price target on Regenxbio to $39 from $34 and keeps an Outperform rating on the shares. The firm noted the first patient at dose level 2 of RGX-202 showed 76% expression and solid CK reduction, and so they walk away with a higher degree of confidence that the higher dose can improve the consistency of response to treatment in a larger trial, without a meaningful increase in safety risk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGNX:
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Regenxbio expects cash to fund operations into 2H25
- Regenxbio reports Q4 EPS ($1.34), consensus ($1.27)
- RGNX Earnings this Week: How Will it Perform?
- Regenxbio resumed with an Outperform at Raymond James